Serum von Willebrand factor levels in patients with inflammatory bowel disease are related to systemic inflammation

G. Meucci, F. Pareti, Maurizio Vecchi, S. Saibeni, C. Bressi, R. De Franchis

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Increased levels of circulating von Willebrand factor (vWF) have been found in patients with inflammatory bowel disease (IBD); this increase may reflect either endothelial damage or systemic inflammation. Our aim was to evaluate serum vWF levels in patients with IBD and their correlation with clinical and biochemical disease activity. Methods: We evaluated serum vWF levels in 32 patients with ulcerative colitis (UC) (10 active with increased acute-phase reactants (APR), 6 active with normal APR, 16 in remission), 27 with Crohn disease (CD) (10 active, 12 quiescent, and 5 quiescent with increased APR), and 31 healthy controls. Results: Mean levels of vWF were 100.1 (standard deviation (s), 51.4) in IBD and 89.9 (s, 36.9) in controls (P = 0.33). Only five (8.47%) patients (three with active UC, one with active CD, and one with inactive CD but increased APR) showed circulating vWF levels higher than the tipper limit of normal (150), compared with 1 (3.2%) of controls (P = 0.32). Among CD patients vWF levels were 80.0 ± 25.4 in patients with quiescent disease and normal APR, 123.3 ± 63.4 in patients with active disease (P = 0.04 versus inactive with normal APR), and 135.8 ± 90.0 in patients with quiescent disease and increased APR (P = 0.059 versus inactive with normal APR). Among UC patients vWF levels were 82.7 ± 35.6 in patients with quiescent disease and normal APR and 125.1 ± 54.2 in those with active disease and increased APR (P = 0.002). Overall, mean vWF levels were significantly higher in patients with increased APR than in patients with normal APR (P = 0.0005) and controls (P = 0.009). Conclusions: Our data show slight but significant increases in serum vWF levels in patients with IBD, which are correlated with signs of systemic inflammation.

Original languageEnglish
Pages (from-to)287-290
Number of pages4
JournalScandinavian Journal of Gastroenterology
Volume34
Issue number3
Publication statusPublished - 1999

Fingerprint

von Willebrand Factor
Acute-Phase Proteins
Inflammatory Bowel Diseases
Inflammation
Serum
Crohn Disease
Ulcerative Colitis

Keywords

  • Crohn disease
  • Endothelial injury
  • Inflammation
  • Inflammatory bowel disease
  • Ulcerative colitis
  • Von Willebrand factor

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Serum von Willebrand factor levels in patients with inflammatory bowel disease are related to systemic inflammation. / Meucci, G.; Pareti, F.; Vecchi, Maurizio; Saibeni, S.; Bressi, C.; De Franchis, R.

In: Scandinavian Journal of Gastroenterology, Vol. 34, No. 3, 1999, p. 287-290.

Research output: Contribution to journalArticle

@article{ed911712990a4ed69015ed9efb40afd7,
title = "Serum von Willebrand factor levels in patients with inflammatory bowel disease are related to systemic inflammation",
abstract = "Background: Increased levels of circulating von Willebrand factor (vWF) have been found in patients with inflammatory bowel disease (IBD); this increase may reflect either endothelial damage or systemic inflammation. Our aim was to evaluate serum vWF levels in patients with IBD and their correlation with clinical and biochemical disease activity. Methods: We evaluated serum vWF levels in 32 patients with ulcerative colitis (UC) (10 active with increased acute-phase reactants (APR), 6 active with normal APR, 16 in remission), 27 with Crohn disease (CD) (10 active, 12 quiescent, and 5 quiescent with increased APR), and 31 healthy controls. Results: Mean levels of vWF were 100.1 (standard deviation (s), 51.4) in IBD and 89.9 (s, 36.9) in controls (P = 0.33). Only five (8.47{\%}) patients (three with active UC, one with active CD, and one with inactive CD but increased APR) showed circulating vWF levels higher than the tipper limit of normal (150), compared with 1 (3.2{\%}) of controls (P = 0.32). Among CD patients vWF levels were 80.0 ± 25.4 in patients with quiescent disease and normal APR, 123.3 ± 63.4 in patients with active disease (P = 0.04 versus inactive with normal APR), and 135.8 ± 90.0 in patients with quiescent disease and increased APR (P = 0.059 versus inactive with normal APR). Among UC patients vWF levels were 82.7 ± 35.6 in patients with quiescent disease and normal APR and 125.1 ± 54.2 in those with active disease and increased APR (P = 0.002). Overall, mean vWF levels were significantly higher in patients with increased APR than in patients with normal APR (P = 0.0005) and controls (P = 0.009). Conclusions: Our data show slight but significant increases in serum vWF levels in patients with IBD, which are correlated with signs of systemic inflammation.",
keywords = "Crohn disease, Endothelial injury, Inflammation, Inflammatory bowel disease, Ulcerative colitis, Von Willebrand factor",
author = "G. Meucci and F. Pareti and Maurizio Vecchi and S. Saibeni and C. Bressi and {De Franchis}, R.",
year = "1999",
language = "English",
volume = "34",
pages = "287--290",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Serum von Willebrand factor levels in patients with inflammatory bowel disease are related to systemic inflammation

AU - Meucci, G.

AU - Pareti, F.

AU - Vecchi, Maurizio

AU - Saibeni, S.

AU - Bressi, C.

AU - De Franchis, R.

PY - 1999

Y1 - 1999

N2 - Background: Increased levels of circulating von Willebrand factor (vWF) have been found in patients with inflammatory bowel disease (IBD); this increase may reflect either endothelial damage or systemic inflammation. Our aim was to evaluate serum vWF levels in patients with IBD and their correlation with clinical and biochemical disease activity. Methods: We evaluated serum vWF levels in 32 patients with ulcerative colitis (UC) (10 active with increased acute-phase reactants (APR), 6 active with normal APR, 16 in remission), 27 with Crohn disease (CD) (10 active, 12 quiescent, and 5 quiescent with increased APR), and 31 healthy controls. Results: Mean levels of vWF were 100.1 (standard deviation (s), 51.4) in IBD and 89.9 (s, 36.9) in controls (P = 0.33). Only five (8.47%) patients (three with active UC, one with active CD, and one with inactive CD but increased APR) showed circulating vWF levels higher than the tipper limit of normal (150), compared with 1 (3.2%) of controls (P = 0.32). Among CD patients vWF levels were 80.0 ± 25.4 in patients with quiescent disease and normal APR, 123.3 ± 63.4 in patients with active disease (P = 0.04 versus inactive with normal APR), and 135.8 ± 90.0 in patients with quiescent disease and increased APR (P = 0.059 versus inactive with normal APR). Among UC patients vWF levels were 82.7 ± 35.6 in patients with quiescent disease and normal APR and 125.1 ± 54.2 in those with active disease and increased APR (P = 0.002). Overall, mean vWF levels were significantly higher in patients with increased APR than in patients with normal APR (P = 0.0005) and controls (P = 0.009). Conclusions: Our data show slight but significant increases in serum vWF levels in patients with IBD, which are correlated with signs of systemic inflammation.

AB - Background: Increased levels of circulating von Willebrand factor (vWF) have been found in patients with inflammatory bowel disease (IBD); this increase may reflect either endothelial damage or systemic inflammation. Our aim was to evaluate serum vWF levels in patients with IBD and their correlation with clinical and biochemical disease activity. Methods: We evaluated serum vWF levels in 32 patients with ulcerative colitis (UC) (10 active with increased acute-phase reactants (APR), 6 active with normal APR, 16 in remission), 27 with Crohn disease (CD) (10 active, 12 quiescent, and 5 quiescent with increased APR), and 31 healthy controls. Results: Mean levels of vWF were 100.1 (standard deviation (s), 51.4) in IBD and 89.9 (s, 36.9) in controls (P = 0.33). Only five (8.47%) patients (three with active UC, one with active CD, and one with inactive CD but increased APR) showed circulating vWF levels higher than the tipper limit of normal (150), compared with 1 (3.2%) of controls (P = 0.32). Among CD patients vWF levels were 80.0 ± 25.4 in patients with quiescent disease and normal APR, 123.3 ± 63.4 in patients with active disease (P = 0.04 versus inactive with normal APR), and 135.8 ± 90.0 in patients with quiescent disease and increased APR (P = 0.059 versus inactive with normal APR). Among UC patients vWF levels were 82.7 ± 35.6 in patients with quiescent disease and normal APR and 125.1 ± 54.2 in those with active disease and increased APR (P = 0.002). Overall, mean vWF levels were significantly higher in patients with increased APR than in patients with normal APR (P = 0.0005) and controls (P = 0.009). Conclusions: Our data show slight but significant increases in serum vWF levels in patients with IBD, which are correlated with signs of systemic inflammation.

KW - Crohn disease

KW - Endothelial injury

KW - Inflammation

KW - Inflammatory bowel disease

KW - Ulcerative colitis

KW - Von Willebrand factor

UR - http://www.scopus.com/inward/record.url?scp=0032907925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032907925&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 287

EP - 290

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 3

ER -